8-K - WHWK - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 14, 2022

AADI BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-38560	61-1547850
(State or other jurisdiction<br> <br>of incorporation)	(Commission<br> <br>File Number)	(I.R.S. Employer<br> <br>Identification No.)
17383 Sunset Boulevard, Suite A250<br> <br>Pacific Palisades, California	90272
---	---
(Address of principal executive offices)	(Zip code)

Registrant’s telephone number, including area code: (424) 474-8055

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
---	---
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
---	---
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
---	---

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading<br> <br>Symbol(s)	Name of each exchange<br> <br>on which registered
Common Stock, par value $0.0001 per share	AADI	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 5.07.	Submission of Matters to a Vote of Security Holders.

Aadi Bioscience, Inc. (the “Company”) held its annual meeting of stockholders on June 14, 2022 (the “Annual Meeting”). At the Annual Meeting, 15,099,527 shares of the Company’s common stock, representing approximately 72% of the voting power of all issued and outstanding shares of common stock of the Company as of April 20, 2022, the record date for the Annual Meeting, and constituting a quorum for the transaction of business, were present in person or by proxy and considered and voted on the following proposals, each of which is described in more detail in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 26, 2022: (1) the election of two Class II directors for terms to expire at the Company’s 2025 annual meeting of stockholders and until their respective successors have been duly elected and qualified; and (2) the ratification of the appointment of BDO USA LLP as the Company’s independent registered public accounting firm for the current fiscal year ending December 31, 2022.

Proposal 1: Election of two Class II directors to serve until the 2025 Annual Meeting of Stockholders and until their respective successors have been elected or qualified.

					Broker
Director	For		Withheld		Non-Votes
Anupam Dalal		11,291,829		454,197		3,353,501
Karin Hehenberger		11,726,212		19,814		3,353,501

Proposal 2: Ratification of the appointment of BDO USA LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.

For	Against	Abstentions
15,019,683	66,252	13,592

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 17, 2022

/s/ Neil Desai, Ph.D.
Neil Desai, Ph.D.
President and Chief Executive Officer